Conference Coverage
Conference Coverage
International study characterizes male breast cancer
Key clinical point: Male breast cancers are similar to female cancers in terms of tumor characteristics and long-term outcomes. Major finding:...
Conference Coverage
Approach can cure even high-risk FL, study suggests
The study showed that many patients transplanted in complete remission (CR) did not relapse and could be considered cured. Patients transplanted...
Conference Coverage
CKT more important than del(17p) in CLL, group finds
The study showed that CKT, defined as 3 or more distinct chromosomal abnormalities, was independently associated with inferior event-free survival...
Conference Coverage
Brentuximab combinations highly active in Hodgkin lymphoma
Photo courtesy of ASH SAN FRANCISCO—Two recent studies have shown combination therapy with brentuximab vedotin to be highly active in newly...
Conference Coverage
LMWH should replace warfarin, doc says
Results of the phase 3 CATCH trial showed that long-term treatment with the LMWH tinzaparin was associated with a 35% lower risk of recurrent...
Conference Coverage
Study confirms IDH2 as therapeutic target in AML, MDS
in the Moscone Center SAN FRANCISCO—The first-in-human study of AG-221 has confirmed IDH2 as a therapeutic target in acute myeloid leukemia (AML...
Conference Coverage
CAR-T cell therapy rolls on in pediatric ALL
Key clinical point: CAR-T cell therapy continues to provide durable responses in early studies of children with refractory ALL. Major finding:...
Conference Coverage
Blinatumomab confirmed as treatment option in MRD+ ALL
SAN FRANCISCO—The first international, multicenter trial in acute lymphoblastic leukemia (ALL) using minimal residual disease (MRD) as a criterion...
Conference Coverage
VALOR: Baby step forward or misstep in AML?
Key clinical point: Vosaroxin plus cytarabine failed to significantly improve overall survival in relapsed or refractory AML, but may offer older...
Conference Coverage
Researchers show CTL019 cells proliferate and persist
Researchers at the University of Pennsylvania, working with CTL019 cells, are beginning to see both of these phenomena in children with relapsed,...
Conference Coverage
Iron chelation improves survival in lower-risk MDS
Photo courtesy of ASH SAN FRANCISCO—Iron chelation therapy significantly improves survival for patients with lower-risk myelodysplastic syndrome...